Why UiPath (PATH) Is Down 12.2% After Agentic AI Pivot And WorkFusion Deal - And What's Next

• UiPath recently broadened its automation platform into agentic AI, completed the acquisition of AI compliance specialist WorkFusion, and prepared to report its fiscal 2026 results on March 11, 2026.
• These moves, combined with rising short interest and a high-profile debate over valuation, are sharpening investor attention on how effectively UiPath can turn its AI ambitions into durable enterprise demand.
• We’ll now examine how UiPath’s push into agentic AI, highlighted by the WorkFusion acquisition, affects the company’s broader investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

UiPath Investment Narrative Recap

To own UiPath, you need to believe that agentic AI can become a core layer of enterprise workflows and that UiPath’s platform can capture that demand despite competition and valuation concerns. The key near term catalyst remains the March 11 fiscal 2026 earnings update, where investors will look for proof that AI products are supporting ARR and margins. Elevated short interest and public skepticism about pricing highlight valuation risk, but the latest news does not materially change the fundamental thesis.

The WorkFusion acquisition is the clearest link between UiPath’s agentic AI story and concrete customer use cases, especially in highly regulated financial services. By adding AI agents focused on financial crime compliance and security, UiPath is expanding its addressable workflows and potentially deepening customer stickiness, which ties directly into the core catalysts around ARR growth, higher value deals and stronger cloud based AI revenue over time.

Yet while the product story is expanding, investors should be aware that rising short interest and valuation concerns could...

Read the full narrative on UiPath (it's free!)

UiPath's narrative projects $1.9 billion revenue and $243.6 million earnings by 2028.

Uncover how UiPath's forecasts yield a $16.40 fair value, a 45% upside to its current price.

Exploring Other Perspectives

Ten Simply Wall St Community members currently place UiPath’s fair value between US$13.87 and US$21.54, reflecting a wide spread of expectations. You can weigh those views against the upcoming earnings catalyst, where progress on AI driven ARR and margins may be critical for how the business is perceived.

Explore 10 other fair value estimates on UiPath - why the stock might be worth as much as 90% more than the current price!

Build Your Own UiPath Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your UiPath research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free UiPath research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate UiPath's overall financial health at a glance.

Contemplating Other Strategies?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Find 53 companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.
• AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com